<DOC>
	<DOCNO>NCT00050726</DOCNO>
	<brief_summary>This investigation sub-study 6-year multinational ESPRIT ( Evaluation Subcutaneous Proleukin Randomized International Trial ) protocol . It compare effectiveness influenza ( FLUVAC ) tetanus-pneumococcal ( TEPVAC ) vaccines HIV-infected patient receive interleukin-2 ( IL-2 ) plus anti-HIV drug receive anti-HIV drug . IL-2 protein naturally produce immune cell call lymphocyte . Lymphocytes patient HIV produce IL-2 normally . The ESPRIT trial evaluate whether HIV-infected patient treated antiretroviral drug plus IL-2 fewer serious infection improve survival receive anti-HIV drug . Participants sub-study drawn patient enrol ESPRIT . They must 18 year age old , HIV infection symptom significant HIV illness . They vaccinate either influenza tetanus pneumococcus , follow : FLUVAC Potentially eligible patient screen FLUVAC study ESPRIT follow-up visit . Those eligible agree participate 10 ml ( 1 tablespoon ) blood drawn ass baseline antibody level receive vaccination . They vaccinate annually 3 year . A blood sample ( 10 ml ) draw 1 month vaccination measure immune response . Some blood drawn study store use research purpose . TEPVAC Participants 10 ml blood drawn ass baseline antibody level . They receive two vaccination ( tetanus pneumococcus ) 12 month enrol ESPRIT another two vaccination 24 month enrollment . A blood sample ( 10 ml ) draw 1 month vaccination measure immune response . Some blood drawn study store use research purpose .</brief_summary>
	<brief_title>Studies Influenza Vaccine Tetanus-Pneumococcal Vaccine HIV-infected Patients Receiving Interleukin-2</brief_title>
	<detailed_description>Evaluation Subcutaneous Proleukin Randomized International Trial ( ESPRIT ) 4,000 patient , 6-year study investigate clinical effect interleukin-2 ( IL-2 ) patient HIV infection . Because size duration study , substudies parent trial perform order improve knowledge regard use IL-2 HIV-infected individual enhance overall scientific output international effort . This protocol serve umbrella ESPRIT substudies perform National Institutes Health Clinical Center .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Heptavalent Pneumococcal Conjugate Vaccine</mesh_term>
	<mesh_term>Interleukin-2</mesh_term>
	<criteria>INCLUSION CRITERIA ESPRIT PROTOCOL : Documentation HIV1 infection license ELISA test confirm second method ( e.g . Western Blot ) ; one follow time : detectable HIV p24 antigen , quantifiable plasma HIV RNA , detectable proviral DNA . Absolute CD4 plus cell count great equal 300/mm ( 3 ) within 45 day prior randomization . ( For patient status postsplenectomy , also CD4 plus cell percentage great equal 20 % . ) No evidence active clinical disease least one year , judgement clinician , AIDSdefining illness ( category C. , CDC , 1993 ) follow condition : extrapulmonary Pneumocystis carinii disease ; multidermatomal Herpes zoster ( great equal 10 lesion noncontiguous site ) ; American trypanosomiasis ( Chagas disease ) CNS ; Penicillium marneffii disease ; visceral leishmaniasis ; nonHodgkin 's lymphoma celltype ; Hodgkin 's lymphoma ; bartonellosis ; microsporidiosis ( great 1 month 's duration ) ; nocardiosis ; invasive aspergillosis ; Rhodococcus equi disease . Age great equal 18 year . Laboratory value ( within 45 day prior randomization ) : AST ALT le equal 5 x upper limit normal ( ULN ) . Total direct bilirubin le 2 x ULN ( Patients hyperbilirubinemia due Gilbert 's syndrome indinavir therapy may serum bilirubin 5 x ULN . ) Creatinine le equal 2.0 mg/dl ( 177 micro mol/L ) . Platelet count great equal 50,000/mm ( 3 ) . On initiate combination antiretroviral therapy time randomization . Antiretroviral therapy include agent ( approved investigational ) administer routine care participation clinical trial expand access program . Signed informed consent form . INCLUSION CRITERIA FLUVAC STUDY : Patients eligible ESPRIT trial eligible FLUVAC study , except patient know allergy egg , history allergic reaction ( ) influenza vaccination influenza vaccine less equal 6 month ESPRIT randomization influenza vaccine season , i.e . September 1st January 31st Northern hemisphere February 1st June 30th Southern hemisphere . The inclusion criterion ESPRIT protocol . EXCLUSION CRITERIA ESPRIT PROTOCOL : Prior rIL2 therapy . Concurrent malignancy require cytotoxic chemotherapy . Use systemic corticosteroid , immunosuppressant , cytotoxic agent within 45 day prior study randomization . Any CNS abnormality require ongoing treatment antiseizure medication . Current historical autoimmune/Inflammatory disease include : Inflammatory bowel disease ( Chron 's disease , ulcerative colitis ) ; Psoriasis ; Optic neuritis ; Any autoimmune/inflammatory disease potentially lifethreatening complication . Pregnancy ( For woman childbearing potential , negative pregnancy test , serum urine , require within 14 day prior randomization . ) Breast feeding . EXCLUSION CRITERIA FLUVAC : As ESPRIT protocol addition patient allergic egg , history allergic reaction ( ) influenza vaccination influenza vaccine less equal 6 month inclusion eligible study . EXCLUSION CRITERIA TEPVAC : As ESPRIT protocol addition patient history allergic reaction study vaccine and/or plan ( give ) vaccination either study vaccine within 12 month follow ESPRIT randomization .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2013</verification_date>
	<keyword>Interleukin-2</keyword>
	<keyword>Immunotherapy</keyword>
	<keyword>HIV</keyword>
	<keyword>IL-2</keyword>
</DOC>